CD44 and neoplasm: Furthermore, novel therapeutic strategies are being explored that leverage CSC surface markers in combination—for example, bispecific antibodies targeting both CD44 and the tumor stroma or CAR-T cells engineered to recognize CSC markers in conjunction with immunosuppressive cues within the TME.